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Frontotemporal dementia and parkinsonism linked to chromosome 17 have been associated with mutations in
the microtubule associated protein tau (MAPT or tau) gene. This disorder is characterized by a large spectrum
of neuronal and glial tau lesions in different brain regions. Pick bodies were found in a family with hereditary
Pick’s disease with the G272V mutation and in several families with other tau mutations in exons 9 and 11–13.
The biochemical composition of Pick bodies varies between these mutations. Until recently, no detailed bio-
chemical characterization of G272V brain material was done owing to unavailability of fresh frozen brain
material. We now report a detailed study using the immunohistochemistry, western blots and electron micro-
scopy of two brains with the G272V mutation that recently became available. Both brains showed severe
neuronal loss in the temporal cortex, whereas in the frontal cortex the loss was less; and abundant Pick bodies
in the dentate gyrus of the hippocampus, and caudate nucleus. The Pick bodies consisted exclusively of three-
repeat (3R) isoforms, as was demonstrated by isoform-specific antibodies and supported by western blot
analysis of sarkosyl-insoluble tau. These observations confirm that this family diagnosed with hereditary
Pick disease meets all the criteria for this condition, including the presence of Pick bodies that are unphos-
phorylated at Ser262 and contain twisted filaments with long periodicity consisting only of 3R tau.
Keywords: brain; focal dementias; neuronal degeneration; tau expression
Abbreviations: NFT = neurofibrillary tangles; PSP = progressive supranuclear palsy; 3R = 3-repeat; 4R = 4-repeat
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Introduction
Pick’s disease is one of the possible pathological entities of
frontotemporal dementia, and is characterized by the pres-
ence of round argyrophilic inclusions (i.e. Pick bodies) in
several regions of the brain. The major constituent of Pick
bodies is the hyperphosphorlyated protein tau. Several other
diseases, such as Alzheimer’s disease or progressive supranuc-
lear palsy (PSP), also contain tau aggregates and therefore,
the general term tauopathies was introduced (Goedert et al.,
1992; Spillantini et al., 1997). The observation, however, that
disease-specific neuronal and glial inclusions showed selective
aggregation of 3-repeat (3R) and 4-repeat (4R) tau isoforms,
led to the further subclassification of tauopathies into 3R and
4R tauopathies. For example, the tau positive inclusions
[neurofibrillary tangles (NFT)] in PSP mainly consist of 4R
tau, whereas tau inclusions in sporadic Pick’s disease (Pick
bodies) are predominantly composed of 3R tau. Therefore,
these conditions are considered to be 4R and 3R tauopathies.
Frontotemporal dementia, linked to chromosome
17q21–22, is a familial group of tauopathies in which neur-
onal and glial tau inclusions can vary in morphology and tau
isoform composition depending on the type and localization
of the mutation in the tau gene. In these families Pick bodies
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are observed in patients with most exon 9 mutations and
several mutations outside exon 10 and flanking regions:
K257T (Rizzini et al., 2000), L266V (Hogg et al., 2003;
Kobayashi et al., 2003), L315R (van Herpen et al., 2003),
S320F (Rosso et al., 2002), Q336R (Pickering-Brown et al.,
2004), G342V (Lippa et al., 2000), K369I (Neumann et al.,
2001), G389R (Murrell et al., 1999; Ghetti et al., 2000). Inter-
estingly, some variance is observed between different muta-
tions in the composition of Pick bodies. Several mutations
give rise to Pick bodies that consist of mainly 3R isoforms,
whereas others consist of a mixture of both 3R and 4R tau,
demonstrating that a detailed analysis (e.g. tau isoform
specific antibodies) should supplement standard (immuno)-
histochemistry results and western blotting.
Hereditary Pick disease as a clinicopathological phenotype
of FTDP-17 has been associated with the G272V mutation in
the tau gene (Sanders, 1939; Schenk, 1959; Groen and Endtz,
1982; Heutink et al., 1997; Spillantini et al., 1998). Biochem-
ical and electron microscopic characterization of the Pick
bodies associated with this mutation had not been performed
owing to unavailability of fresh frozen brain material. Fresh
frozen brain material of two patients from such a family has
recently become available and is characterized in this paper by
means of immunohistochemistry, western blot and electron
microscopy. Using isoform-specific antibodies (de Silva et al.,
2003) we were able to determine that the hereditary Pick
disease in this family (Fig. 1), originally described as early
as 1939 by Sanders et al. (1939) and later by Schenk (1959)




At the age of 45 years this patient increasingly created problems at
work as a legal employee as a result of conflicts with her colleagues.
At home she became increasingly apathetic, neglected household
affairs and personal hygiene. Owing to impulsiveness and loss of
attention, driving a car became dangerous. Her impaired financial
judgement resulted in huge debts. Neurological examination of the
patient showed intact language and memory functions, but impaired
planning and abstract thinking. Cranial nerves were intact. Upper
and lower extremities showed normal muscle tone and strength;
tendon reflexes were symmetrically intact. MRI showed mild atrophy
of the anterior and temporal lobes. In the next 2 years, she became
socially withdrawn, and even avoided visits by family members. Her
condition gradually deteriorated over the next 5 years. At the age of
50 years she was admitted to a psychogeriatric nursing home. She
died at the age of 54 years. Family history showed that her father
and her eldest brother had died from Pick’s disease at the age of
53 and 47 years, respectively, whereas a sister is currently affected and
still alive.
Patient II
At the age of 52 years, this woman developed inappropriate and
repetitive (verbal and motor) behaviour and became stubborn
and emotionally blunt. At her first out-clinic visit, the patient showed
impaired orientation and naming, recurring utterances and persev-
erations, but normal memory and visuoconstructive functions. Cra-
nial nerves were intact. Muscle-tone, strength and reflexes of upper
and lower extremities were normal. At that time CT scan showed
mild symmetrical temporal atrophy. She was admitted to a psycho-
geriatric nursing home at the age of 58 years, where she died at the age
of 67 years, 15 years after the onset of the disease. Family history
showed that her father and her brother had died from Pick’s disease
at the age of 55 and 54 years, respectively, whereas her youngest son
already developed dementia at the age of 44 years.
Brain pathology and staining
Routine staining with haematoxylin–eosin, Bodian, Gallyas and
Congo red was performed. Immunohistochemistry for tau protein
made use of phosphorylation-dependent [AT8 (1:40, Innogenetics,
Ghent, Belgium), AT180 (1:500, Innogenetics), AT270 (1:500,
Innogenetics), PHF1 (1:500, donated by P. Davies), MC1 (1:25,
Fig. 1 Family tree of the G272V family with hereditary Pick’s disease. Males are depicted as squares, females as circles. Affected members
are shown in half black, members suspected to be affected as quarter black. I and II represent patients I and II, respectively.
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donated by P. Davies) and 12E8 (1:500, donated by P. Seubert,
Elan Pharmaceuticals, San Francisco, CA)] and phosphorylation-
independent [BR01 (1:500, Innogenetics), Tau 2 (1:100, Sigma Fine
Chemicals, St Louis, MO)] antibodies. Antibodies directed against
ubiquitin (1:500, Dako, Glostrup, Denmark), b-amyloid (1:100,
Dako), a-synuclein (1:500, Chemicon, Temecula, CA) and glial
fibrillary acidic protein (GFAP; 1:500, Dako) were also used. Stain-
ing was revealed using the biotin/avidin Vectastain system (Vector
Laboratories, Burlingame, CA), as described (Rosso et al., 2001).
For staining with specific anti-tau phospho-specific Ser262 anti-
body (577814, Calbiochem, 1:500), tissue sections were boiled in
citrate buffer for 5 min, treated with 99% formic acid for 20 s
and stored overnight at room temperature. Tau antibodies specific
against 3R (RD3, Upstate, Charlesville) and 4R tau isoforms (RD4,
Upstate, Charlesville) were used (de Silva et al., 2003) to investigate
the tau isoform composition of Pick bodies. Sections from the two
G272V cases as well as an Alzheimer’s disease and a PSP control were
pretreated by pressure-cooking in sodium citrate buffer (pH 6) for
5 min, followed by incubation with RD3 (1:6000) and RD4 (1:100)
at 4C overnight.
Tau haplotyping
MAPT H1/H2 haplotypes were determined by SNPs rs9468, rs916793
and rs1800547 using Taqman SNP genotyping assay and 20 ng of
genomic DNA according to the manufacturer’s protocol.
Tau extraction, immunoblotting and
electron microscopy
Sarkosyl-soluble and insoluble tau proteins were extracted from the
gyrus frontalis inferior, gyrus frontalis medialis, gyrus temporalis
medialis, cerebellum, hippocampus and caudate of both patients
as described (Goedert et al., 1992). Dephosphorylation and immuno-
blotting using the phosphorylation-independent anti-tau antibody
H-7 (1:2000) (Mercken et al., 1992) or the 3R specific anti-tau anti-
body RD3 (1:2000) were performed as described (Rizzu et al., 2000;
Rosso et al., 2001). Aliquots of sarkosyl-insoluble tau extracted from
the gyrus frontalis medialis were processed for electron microscopy
as described (Goedert et al., 1992; Lee et al., 2001). The phosphoryla-
tion dependent anti-tau antibody AT8 was gold conjugated and used
at a dilution of 1:100.
Results
Pathology
Severe frontal and temporal atrophy with enlarged lateral
ventricles was present in both brains. Brain weights were
872 and 897 g for brain I and brain II, respectively. The
hippocampus and amygdala showed atrophy in both brains,
but much more severe in brain II. The anterior part of the
caudate nucleus and putamen were severely atrophic in
brain II. Substantia nigra and locus coeruleus were normally
pigmented in both brains. In both brains, neuronal loss and
gliosis were severe in all layers, except layer IV, of the temporal
and insular cortices, although more pronounced in brain II.
The frontal cortex showed a mild neuronal loss and gliosis
in brain I and a moderate loss in brain II. The cingular cortex,
the parietal and occipital cortices were normal, except
for some senile plaques in the occipital cortex of brain II.
Both brains showed moderate neuronal loss in CA1 and
CA2, and severe loss in subiculum, entorhinal cortex and
amygdala. The caudate nuclei had a normal appearance,
but showed severe loss of large neurones in both brains.
Neuronal loss in the substantia nigra was severe in brain I
and mild in brain II.
Bodian and Gallyas staining revealed a few NFT in the
frontal cortex in brain I and in both patients many round
inclusions (Pick bodies) in the granular cells of the dentate
gyrus and the small neurones of the caudate nucleus.
Immunohistochemical staining with AT8 showed numer-
ous Pick bodies, which were abundant in the granular cells
of the dentate gyrus of brain I, whereas the dentate gyrus of
brain II showed more curvilinear deposits and a few Pick
bodies (Fig. 2A and B). NFT were present in a few neurones
of the CA, the subiculum and the entorhinal cortex, the amy-
gdala and the thalamus of both brains. Some tau-positive
neurones and a few glial cells were present in the frontal cortex
(Fig. 3C), whereas almost no tau staining was seen in the
temporal cortex. Abundant tau inclusions were present in
small neurones of the caudate nucleus (Fig. 3A). Tau staining
was positive in several neurones of the substantia nigra of
brain II, but was absent in brain I. A few tau-positive neurones
were present in locus ceruleus, pons and brainstem in both
brains. The cingular, parietal and occipital cortices in both
brains did not show tau-positive inclusions. A few tau-
positive neuronal inclusions and some dystrophic neurites
were seen in the dentate nucleus of the cerebellum (Fig. 3D).
Immunohistochemistry with PHF1 and AT180 gave a similar,
although less intense, staining. Staining with the 3R specific
antibody, RD3, showed many Pick bodies in the granular
cells of the dentate gyrus of brain I (Fig. 2C), whereas
more diffuse cytoplasmic staining and a few Pick bodies were
found in the granular cells of brain II (Fig. 2D). Abundant
Pick bodies were present in the small neurones of the caudate
nucleus of both brains (Fig. 3B). RD4 staining was negative for
all Pick bodies in both brains (Fig. 2E), but gave positive
staining of a few NFT in CA1 and CA2 of brain I (Fig. 2G)
and a diffuse cytoplasmic staining. In addition, RD4 gave
positive staining of a few NFT in CA1 and CA2 of brain
I (Fig. 2G) and a diffuse cytoplasmic staining of some granular
cells in the dentate gyrus of brain II (Fig. 2F). A faint cyto-
plasmatic staining of a few small neurones in the caudate
nucleus was seen in both brains (data not shown). The
RD4 staining of Alzheimer’s disease and PSP controls showed
NFT in Alzheimer’s disease, and gave NFT and tau-positive
glial inclusions in the PSP brain (Fig. 2H). Pick bodies did
not stain with the antibodies 12E8 and PS262, but weak
staining was observed in some Pick bodies when stained
for ubiquitin. Staining for a-synuclein and b-amyloid was
negative in both brains.
Mutation analysis and haplotyping
Mutation analysis of both patients had already been done
as described before (Spillantini et al., 1998). In addition,
G272V patients show 3R tau pathology Brain (2005), 128, 2645–2653 2647







Fig. 2 Immunohistochemistry (Pick bodies). Immunohistochemistry with AT8 antibody shows numerous Pick bodies in the granular
cells of the dentate gyrus of brain I (A) and some Pick bodies and curvilinear cytoplasmatic deposits in the same cells in brain II (B).
The RD3 antibody gives positive staining of numerous Pick bodies (although less than with AT8) in brain I (C), and some Pick bodies and
more diffuse cytoplasmatic staining of many granular cells in brain II (D). Staining with RD4 antibody is negative for Pick bodies (E),
but shows diffuse cytoplasmatic staining in a few granular cells in brain II (F), and of a few NFT in CA1 of brain I (G). NFT and glial
inclusions in a PSP brain were positive for RD4 staining (H). Scale bar A through H = 100 mm.
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tau haplotypes of both mutant and wild-type alleles were
determined. Since both patients showed a H1/H1 haplotype,
both mutant alleles were expressed in the H1 background.
Characterization of frozen brain material
Western blots of the sarkosyl-insoluble fraction of tau from
several regions (including the frontal and temporal cortices)
mainly showed 60 and 64 kDa bands. In some regions
(i.e. frontal cortex and caudate) an extra band of 68 kDa
band was also present (Fig. 4A). This pattern is typical for
Pick’s disease pathology (Delacourte et al., 1998). Interest-
ingly, the sarkosyl-insoluble tau from the cerebellum in
brain II also showed 60 and 64 kDa bands, which is in accord-
ance with the presence of tau inclusions observed in the
immunohistochemistry.
After dephosphorylation, sarkosyl-insoluble tau consisted
predominantly of 3R tau, and the amount of 3R0N and 3R1N
was much higher than 3R2N. The 3R0N isoform ran some-
what lower on gel than the corresponding recombinant
tau band (Fig. 4B), as a result of the high amount of alkaline
phosphatase used in this dephosphorylation step, which was
confirmed by using the 3R-specific antibody (Fig. 5). The
small amount of 4R tau observed consisted mainly of 4R1N
(Fig. 4B), although, probably owing to the sensitivity of the
monoclonal antibody, some other 4R bands could also be
detected.
Western blots of the sarkosyl-soluble fraction from the
frontal and temporal cortices showed all isoforms (Fig. 4C).
Sarkosyl-insoluble tau filaments
When the sarkosyl-insoluble fractions of both patients were
evaluated under the EM, it contained AT-8 positive tau fila-
ments (Fig. 6A) that resembled ribbon twisted filaments
(Fig. 6B). They had however a longer periodicity (>110 nm)
than those found in Alzheimer’s disease patients, but their
width was similar (20 nm).
Discussion
The present study shows abundant Pick bodies in the caudate
nucleus and dentate gyrus of the hippocampus in two patients
with the G272V mutation in exon 9 of the tau gene. Further-
more, we showed, that sarkosyl-insoluble tau extracted from
Pick bodies consists predominantly of 3R tau isoforms.
Sarkosyl-insoluble tau filaments were shown to be ribbon
twisted, with long periodicity.
The presence of Pick bodies in the two G272V brains could
be detected using both Bodian and Gallyas silver staining, as
has been also observed in the L266V mutation (Hogg et al.,
2003). This is in contrast to other tau mutations and sporadic
Pick cases, in which Pick bodies are Bodian positive and
Gallyas negative (Neumann et al., 2001; Ikeda et al., 2002;
Fig. 3 Immunohistochemistry with AT8 antibody shows numerous Pick bodies in small and medium-sized neurones of the caudate
nucleus of both brains (A), which are strongly immunoreactive for RD3 antibody (B) and negative with RD4 antibody (not shown).
AT8 staining shows a few Pick bodies and tau-positive neurones in the frontal cortex (C) and the dentate nucleus of the cerebellum (D).
Scale bar = 100 mm.
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Fig. 4 Western blots of tau protein extracted from patients’ brains. (A) Sarkosyl-insoluble tau extracted from several brain regions
of patients I and II. AD, sarkosyl-insoluble tau extracted from Alzheimer’s diseased brain. (B) Dephosphorylated sarkosyl-insoluble
tau from several brain regions of patients I and II. (C) Dephosphorylated sarkosyl-soluble tau from several brain regions of patients I and II.
AD, sarkosyl-soluble tau extracted from the same region of Alzheimer’s diseased brain; Rec, recombinant tau consisting of all six
isoforms. Names are according to tau isoforms. Sizes are in kDa.
Fig. 5 Western blots of tau protein extracted from patients’
brains stained with RD3. (A) Hyperphosphorylated
sarkosyl-insoluble tau stained with the 3R specific antibody RD3.
II, sarkosyl-insoluble tau extracted from brain material of patient II;
PiD, sarkosyl-insoluble tau extracted from a classical Pick’s
disease patient; AD, sarkosyl-insoluble tau extracted from brain
material of an Alzheimer’s disease patient. Sizes are in kDa.
(B) Dephosphorylated sarkosyl-insoluble tau stained with the 3R
specific antibody RD3. Rec, recombinant tau consisting of all six
isoforms. Since the antibody is 3R tau specific, only the 3R
isoforms are stained. Names are according to tau isoforms.
Fig. 6 Electron micrographs of G272V tau filaments.
Electron microscopic examination of sarkosyl-insoluble tau
extracted from the frontal lobe of patients I and II. (A) A tau
filament taken from patient I. Both patients showed similar
filaments. (B) Sarkosyl-insoluble tau labelled with gold
conjugated AT8. In both micrographs the black bar
depicts 50 nm.
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Rosso et al., 2002; Kobayashi et al., 2004). Although it has
been suggested that this difference could be explained by the
increased affinity of the Gallyas method for 4R tau (Dickson,
2001), in our experiments, by using isoform specific antibod-
ies, no 4R tau was detected in these Pick bodies. Therefore, an
alternate explanation for this observation must be found.
The distribution of the Pick bodies to the caudate nucleus
differs from most sporadic Pick’s disease cases and several tau
mutations, in which Pick bodies are abundant in the frontal
and temporal cortices (Kosaka et al., 1991; Murrell et al., 1999;
Lippa et al., 2000; Neumann et al., 2001; Zhukareva et al.,
2002; Pickering-Brown et al., 2004). The absence of Pick
bodies in the temporal cortex may be related to the severe
neuronal loss; however Pick bodies were also absent in the
frontal cortex, which was much less affected. The presence of
tau-positive lesions in the dentate nucleus of the cerebellum is
in agreement with the presence of insoluble tau protein on
western blot (Fig. 4A).
The mild glial or astrocytic tau pathology in the present
G272V brains contrasts with several other mutations with
Pick bodies, in which glial or astrocytic tau pathology was
much more pronounced (Murrell et al., 1999; Lippa et al.,
2000; Neumann et al., 2001; Kobayashi et al., 2003, 2004;
van Herpen et al., 2003). This variable extent of glial or astro-
cytic tau pathology in conjunction with the presence of Pick
bodies might reflect an intermediate step in the neurodegen-
erative process comparable with the astrocytic reaction that is
specific for 4R tau isoforms.
The positive RD3 (Fig. 2B and D) and negative RD4 stain-
ing of Pick bodies reflects the exclusive accumulation of 3R
tau isoforms in the Pick bodies of the G272V patients. Our
western blot data, which show the presence of 60 and 64 kDa
bands in the sarkosyl-insoluble tau fraction, and mainly 3R
isoforms after dephosphorylation confirm these immunohis-
tochemical findings. We reason that the low levels of 4R tau
observed on these western blots correspond to the presence of
some NFT in the CA1 and CA2 in brain I; the diffuse or faint
positive cytoplasmatic staining of some granular cells and of
few small neurones in the caudate nucleus of brain II that
could also be detected by our sensitive monoclonal RD4
antibody in the immunostaining.
With ageing, tau proteins can become insoluble, and
sometimes contaminate the preparation of the so-called
‘pathological tau aggregates’. We reason, therefore, that the
presence of NFT in our patients is a part of the normal ageing
process and not a part of the disease. This contamination has
also been described in several other neurodegenerative
diseases (Hof et al., 1992a, b, c). The diffuse cytoplasmic
staining in some granular cells of the other brain, however,
is interesting and should be investigated for other mutations.
Therefore, our observations are in accordance with the
generally accepted concept of Pick bodies, which is, to be
exclusively composed of 3R tau isoforms (Delacourte et al.,
1996, 1998). Other FTDP-17 mutations with a Pick-like
phenotype have also shown the presence of 3R and 4R tau
isoforms on western blots of sarkosyl-insoluble tau. In these
studies, this might also be explained by the co-occurrence of
glial pathology or NFT (Murrell et al., 1999; Lippa et al., 2000;
Neumann et al., 2001; Rosso et al., 2002; van Herpen et al.,
2003), as the composition of Pick bodies was not tested using
isoform-specific antibodies.
The absence of staining, using the antibodies 12E8 and
PS262 with and without formic acid pretreatment, indicates
the lack of phosphorylation of the serine at position 262, and
agrees with the observations of most other studies of Pick’s
disease (Delacourte et al., 1996, 1998; Probst et al., 1996; Arai
et al., 2001; Ikeda et al., 2002). It is, however, in contrast with
the more recent observations, where Pick bodies, following
formic acid pretreatment, showed some immunoreactivity
with the antibody 12E8 and strong staining with PS262
(Ferrer et al., 2002; Arai et al., 2003). Since this immuno-
reactivity was even observed in patients showing Pick bodies
that consisted predominantly of 3R tau isoforms (Arai et al.,
2003), we reason that this observation cannot be explained by
a specific reaction with phosphorylated Ser262 of 4R tau.
Since Pick bodies in the G272V and L266V mutations con-
sist only of 3R tau, it is an interesting question whether exon 9
mutations induce a more efficient aggregation of 3R tau com-
pared with 4R tau. However, in vitro studies showed a higher
aggregation rate of 3R and 4R L266V tau (Hogg et al., 2003).
In addition, another exon 9 mutation (i.e. I260V) causes a 4R
tauopathy with NFT (PSP) and shows a higher aggregation
rate for 4R tau compared with 3R tau (Hasegawa et al., 1998;
Barghorn et al., 2000; Grover et al., 2003).
The tau positive filaments from both patients were shown
to have a very long periodicity. Although most filaments
described in sporadic Pick’s disease are straight filaments,
several cases described PHF-like filaments with a long peri-
odicity of 120–160 nm, whereas the filament width has been
shown to vary between 13 and 26 nm (Kato and Nakamura,
1990; Murayama et al., 1990; Dickson, 2001). This means that
the observed width of 13 nm is also according to the filaments
described in the literature.
The present immunohistochemical and biochemical
investigations show that our patients meet all of the criteria
to be diagnosed as hereditary Pick’s disease. However, patho-
logy-proven cases of Pick’s disease are clinically indistinguish-
able from FTD cases without Pick bodies. In addition, Pick’s
disease is etiologically heterogeneous by the fact that it has
been associated with different types of tauopathy (3R, com-
bined 3R-4R or even 4R) (Zhukareva et al., 2002) as well as
with combined 3R-4R FTDP-17 cases (Pickering-Brown et al.,
2000, 2004; van Herpen et al., 2003). Conversely, other tau
mutations that also have a combined 3R-4R isoform profile
[V337M and R406W (Hutton et al., 1998; Poorkaj et al.,
1998)] are not classified as Pick’s disease because these
patients show only presence of neurofibrillary tangles. This
means that Pick’s disease is nothing more than another con-
notation for the presence of Pick bodies. We would suggest to
bring the term Pick’s disease back into clinical practice and to
use the pathological classification of 3R, 4R or mixed type of
tauopathy for etiological refinement.
G272V patients show 3R tau pathology Brain (2005), 128, 2645–2653 2651







We also suggest to include immunohistochemistry using
isoform specific tau antibodies to supplement the results of
western blots of other FTDP-17 and atypical tauopathy cases
in order to refine tau pathology. This detailed analysis will
allow us to include also the somewhat atypical Pick cases and
will lead to the identification of new subgroups. Possibly these
groups will help us to reveal new and distinct disease pathways
that could help us in understanding the pathogenesis of all
neurodegenerative diseases better.
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